801283-95-4
Chemical Structure
Faldaprevir
Synonym(s): BI 201335
- CAS No.: 801283-95-4
- Formula:C40H49BrN6O9S
- Molecular Weight:869.82
IUPAC Name: (1R,2S)-1-((2S,4R)-4-((8-bromo-2-(2-isobutyramidothiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxamido)-2-vinylcyclopropane-1-carboxylic acid
InChIKey: LLGDPTDZOVKFDU-XUHJSTDZSA-N
SMILES: O=C([C@H](C[C@H]1OC2=CC(C3=CSC(NC(C(C)C)=O)=N3)=NC4=C2C=CC(OC)=C4Br)N(C1)C([C@H](C(C)(C)C)NC(OC5CCCC5)=O)=O)N[C@@]([C@@H]6C=C)(C6)C(O)=O
Biological Activity: Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Faldaprevir | 98.58% | Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Faldaprevir-d7 | Faldaprevir-d7 is deuterium labeled Faldaprevir. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Faldaprevir-d6 | Faldaprevir-d6 is deuterium labeled Faldaprevir. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Llinàs-Brunet M, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem. 2010 Sep 9;53(17):6466-76. [Content Brief]
- [2]. Zeuzem S, et al. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther. 2013;18(8):1015-9. [Content Brief]
